Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients

Purpose. To evaluate the activity and safety of ecteinascidin (ET-743) in pretreated patients with advanced or metastatic soft tissue and bone sarcoma. Patients or subjects. Eighty-nine patients received ET-743 as a 24-hour continuous infusion at a dose of 900–1500 μg/m(2) every 3 weeks. Results. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Huygh, G., Clement, Paul M. J., Dumez, H., Schöffski, P., Wildiers, H., Selleslach, J., Jimeno, J. M., Wever, I. De, Sciot, R., Duck, L., Van Oosterom, A. T.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1820623/
https://www.ncbi.nlm.nih.gov/pubmed/17496996
http://dx.doi.org/10.1155/SRCM/2006/56282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1820623/
https://www.ncbi.nlm.nih.gov/pubmed/17496996
http://dx.doi.org/10.1155/SRCM/2006/56282

Ejemplares similares